Caribou Biosciences, Inc. Common Stock (CRBU)

Price$1.92

Value ScoreC

Growth ScoreC

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-8.96%

Price vs S&P 500 (4W)-1.02%

VGM Score49.11

Market Capitalization$190.43M

All Metrics

Book Value / Share (Quarterly)$1.05

P/TBV (Annual)1.66x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-6.95%

Cash Flow / Share (Quarterly)$-1.05

Price vs S&P 500 (YTD)12.60%

Net Profit Margin (TTM)-1189.14%

EPS (TTM)$-1.42

10-Day Avg Trading Volume1.93M

EPS Excl Extra (TTM)$-1.42

Revenue Growth (5Y)-2.02%

EPS (Annual)$-1.59

ROI (Annual)-121.24%

Net Profit Margin (5Y Avg)-906.06%

Cash / Share (Quarterly)$1.21

Revenue Growth QoQ (YoY)1.87%

ROA (Last FY)-84.47%

Revenue Growth TTM (YoY)12.96%

EBITD / Share (TTM)$-1.46

ROE (5Y Avg)-51.64%

Operating Margin (TTM)-1257.42%

Cash Flow / Share (Annual)$-1.18

P/B Ratio1.87x

P/B Ratio (Quarterly)1.80x

Net Income / Employee (Annual)$-1,527,100

EV / Revenue (TTM)15.92x

Net Interest Coverage (TTM)-16978.50x

ROA (TTM)-71.99%

EPS Incl Extra (Annual)$-1.59

Current Ratio (Annual)5.71x

Quick Ratio (Quarterly)6.10x

3-Month Avg Trading Volume1.45M

52-Week Price Return76.15%

Revenue / Employee (TTM)$115,500

Tangible BV / Share (Quarterly)$4.50

P/S Ratio (Annual)17.06x

Asset Turnover (Annual)0.06x

52-Week High$3.54

Operating Margin (5Y Avg)-972.94%

EPS Excl Extra (Annual)$-1.59

CapEx CAGR (5Y)33.54%

26-Week Price Return-1.03%

Quick Ratio (Annual)5.60x

13-Week Price Return12.28%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.22x

Enterprise Value$178.37M

Revenue / Share Growth (5Y)-11.33%

Asset Turnover (TTM)0.06x

Revenue / Employee (Annual)$115,000

Pretax Margin (Annual)-1332.33%

Cash / Share (Annual)$1.46

3-Month Return Std Dev70.09%

Net Income / Employee (TTM)$-1,373,400

ROE (Last FY)-121.24%

Net Interest Coverage (Annual)-852.54x

EPS Basic Excl Extra (Annual)$-1.59

Receivables Turnover (TTM)12.35x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.42

Receivables Turnover (Annual)6.51x

ROI (TTM)-100.13%

P/S Ratio (TTM)17.00x

Pretax Margin (5Y Avg)-906.19%

Revenue / Share (Annual)$0.12

Tangible BV / Share (Annual)$4.93

Price vs S&P 500 (52W)51.78%

Year-to-Date Return20.75%

5-Day Price Return-20.99%

EPS Normalized (Annual)$-1.59

ROA (5Y Avg)-39.48%

Net Profit Margin (Annual)-1327.40%

Month-to-Date Return-18.64%

Cash Flow / Share (TTM)$-1.36

EBITD / Share (Annual)$-1.65

Operating Margin (Annual)-1411.43%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-51.64%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.42

P/TBV (Quarterly)1.26x

P/B Ratio (Annual)1.22x

Pretax Margin (TTM)-1194.05%

Book Value / Share (Annual)$1.28

Price vs S&P 500 (13W)4.03%

Beta2.42x

Revenue / Share (TTM)$0.12

ROE (TTM)-100.13%

52-Week Low$1.04

vGradeC

gGradeC

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.26est. -0.32

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.29

4.27

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
CRBUCaribou Biosciences, Inc. Common Stock	C	C	B	$1.92
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00

About

Caribou Biosciences is a clinical-stage CRISPR biopharmaceutical company developing next-generation cell therapies using its proprietary chRDNA platform. The company focuses on creating allogeneic CAR-T and CAR-NK cell therapies designed to treat patients with serious diseases. Caribou's genome-editing approach aims to overcome existing limitations in cell-based cancer therapeutics.